| | |
n(%)
|
P-Value
|
|---|
| | |
Positive (n = 23)
|
Negative (n = 100)
|
|---|
|
Age Groups
|
≤70 years
|
14(60.9)
|
63(63)
|
0.849
|
|
> 70 years
|
9(39.1)
|
37(37)
|
|
Total gleason score
|
6
|
1(4.3)
|
38(38)
|
< 0.001
|
|
7
|
3(13)
|
26(26)
|
|
8
|
5(21.7)
|
22(22)
|
|
9
|
14(60.9)
|
14(14)
|
|
WHO grade groupª
|
Grade 1
|
1(4.3)
|
38(38)
|
< 0.001
|
|
Grade 2
|
2(8.7)
|
23(23)
|
|
Grade 3
|
1(4.3)
|
3(3)
|
|
Grade 4
|
5(21.7)
|
22(22)
|
|
Grade 5
|
14(60.9)
|
14(14)
|
|
Tumor Quantificationª
|
< 10%
|
1(4.3)
|
22(22)
|
0.007
|
|
10–50%
|
3(13)
|
32(32)
|
|
> 50%
|
19(82.6)
|
46(46)
|
|
Perineural invasion
|
Present
|
16(69.6)
|
30(30)
|
< 0.001
|
|
Absent
|
7(30.4)
|
70(70)
|
|
Lymphovascular invasionª
|
Present
|
0(0)
|
3(3)
|
1.000
|
|
Absent
|
23(100)
|
97(97)
|
|
Extraprostatic extensionª
|
Present
|
0(0)
|
7(7)
|
0.346
|
|
Absent
|
23(100)
|
93(93)
|
|
Seminal vesicle invasion ª
|
Present
|
2(8.7)
|
2(2)
|
0.158
|
|
Absent
|
21(91.3)
|
98(98)
|
|
Recurrence
|
Yes
|
19(82.6)
|
14(14)
|
< 0.001
|
|
No
|
4(17.4)
|
86(86)
|
- Chi square test was applied
- ªFisher exact test applied
- P-Value≤0.05, considered as significant
